相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Talia Golan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Targeting hypoxic tumor microenvironment in pancreatic cancer
Jinxin Tao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival
S. -A. Safi et al.
PANCREATOLOGY (2021)
A peptide-based neoantigen vaccine for patients with advanced pancreatic cancer refractory to standard treatment.
Liu Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Gemcitabine (Gem) and nab-paclitaxel (NP) +/- nivolumab (nivo) +/- CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.
Mark H. O'Hara et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Technical advances in surgery for pancreatic cancer
M. Schneider et al.
BRITISH JOURNAL OF SURGERY (2021)
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Marcus Noel et al.
INVESTIGATIONAL NEW DRUGS (2020)
Is there a Role for the Appleby Procedure in 2020? Results from a Matched-Pair-Analysis
Thomas Malinka et al.
ANTICANCER RESEARCH (2020)
The Impact of Sarcopenia on Postoperative Course following Pancreatoduodenectomy: Single-Center Experience of 110 Consecutive Cases
Leonardo Centonze et al.
DIGESTIVE SURGERY (2020)
A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors
Yong Fang et al.
CLINICAL CANCER RESEARCH (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?
Qi Zhou et al.
FRONTIERS IN ONCOLOGY (2020)
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny et al.
NATURE MEDICINE (2020)
Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis
Arsen Osipov et al.
CLINICAL CANCER RESEARCH (2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?
Erryk S. Katayama et al.
Oncotarget (2020)
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramesh K. Ramanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
Yongwoo David Seo et al.
CLINICAL CANCER RESEARCH (2019)
Reactive oxygen species: a volatile driver of field cancerization and metastasis
Zehuan Liao et al.
MOLECULAR CANCER (2019)
Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer
Alex B. Blair et al.
CLINICAL CANCER RESEARCH (2019)
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
Divya Thomas et al.
MOLECULAR CANCER (2019)
Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer
Yuqing Zhang et al.
MOLECULAR CANCER RESEARCH (2019)
Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study
Fernando Rivera et al.
PANCREATOLOGY (2019)
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
Timothy M. Nywening et al.
GUT (2018)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Myeloid cell heterogeneity in cancer: not a single cell alike
Mate Kiss et al.
CELLULAR IMMUNOLOGY (2018)
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.
David Linehan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Alexander N. Shoushtari et al.
JAMA ONCOLOGY (2018)
Recent advances in small molecule based cancer immunotherapy
Binbin Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
A catalase-loaded hierarchical zeolite as an implantable nanocapsule for ultrasound-guided oxygen self-sufficient photodynamic therapy against pancreatic cancer
Dehong Hu et al.
NANOSCALE (2018)
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
Andrea Wang-Gillam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Rachna T. Shroff et al.
JCO PRECISION ONCOLOGY (2018)
Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway
Graziana Digiacomo et al.
CELL ADHESION & MIGRATION (2017)
The role of tumor microenvironment in therapeutic resistance
Beomseok Son et al.
ONCOTARGET (2017)
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
Koji Shindo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar et al.
LANCET ONCOLOGY (2017)
Total mesopancreas excision for the treatment of pancreatic head cancer
Jingyong Xu et al.
JOURNAL OF CANCER (2017)
Targeted Therapy and Immunosuppression in the Tumor Microenvironment
Michael J. Allegrezza et al.
TRENDS IN CANCER (2017)
Immunotherapy for Breast Cancer: What Are We Missing?
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2017)
Current state of immunotherapy for non-small cell lung cancer
Jyoti Malhotra et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Pancreatic Cancer Surgery The New R-status Counts
Oliver Strobel et al.
ANNALS OF SURGERY (2017)
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer
Nicholas J. Roberts et al.
CANCER DISCOVERY (2016)
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
Colin W. Steele et al.
CANCER CELL (2016)
Current progress in immunotherapy for pancreatic cancer
Kelly Foley et al.
CANCER LETTERS (2016)
Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight
Norihiro Sato et al.
CANCER SCIENCE (2016)
Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression
Hanane Laklai et al.
NATURE MEDICINE (2016)
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang et al.
NATURE MEDICINE (2016)
Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer
Lun Zhang et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2016)
Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma
Andrew Hendifar et al.
PLOS ONE (2016)
The role of wild type RAS isoforms in cancer
Bingying Zhou et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
Cancer: An Oxidative Crosstalk between Solid Tumor Cells and Cancer Associated Fibroblasts
Alessandro Arcucci et al.
BIOMED RESEARCH INTERNATIONAL (2016)
CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma
Timothy Chao et al.
CANCER IMMUNOLOGY RESEARCH (2016)
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
Paul R. Kunk et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The role of myeloid cells in cancer therapies
Camilla Engblom et al.
NATURE REVIEWS CANCER (2016)
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Albert Lo et al.
CANCER RESEARCH (2015)
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Alan Serrels et al.
CELL (2015)
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Clifford J. Whatcott et al.
CLINICAL CANCER RESEARCH (2015)
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
Stefano Ugel et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC).
Andrea Wang-Gillam et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Kazuyoshi Shiga et al.
CANCERS (2015)
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Kevin C. Soares et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
Targeting FAK in human cancer: from finding to first clinical trials
Vita M. Golubovskaya
FRONTIERS IN BIOSCIENCE-LANDMARK (2014)
High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma
Martin B. Pedersen et al.
HISTOPATHOLOGY (2014)
Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
Peter J. Murray et al.
IMMUNITY (2014)
Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis
Meixiao Shen et al.
PLOS ONE (2014)
Chronic Inflammation and Cytokines in the Tumor Microenvironment
Glauben Landskron et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy
Eric R. Lutz et al.
ONCOIMMUNOLOGY (2014)
Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition
Carlos E. Prada et al.
ACTA NEUROPATHOLOGICA (2013)
Macrophage Regulation of Tumor Responses to Anticancer Therapies
Michele De Palma et al.
CANCER CELL (2013)
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
Jonathan B. Mitchem et al.
CANCER RESEARCH (2013)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz et al.
GUT (2013)
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Jing Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
Jeffrey M. Hardacre et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Sunitha Kakarla et al.
MOLECULAR THERAPY (2013)
Nuclear FAK: a new mode of gene regulation from cellular adhesions
Ssang-Taek Steve Lim
MOLECULES AND CELLS (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤ 25 mm in Size and ≤ 1 Involved Lymph Nodes
Pavan Tummala et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2013)
Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
Inge Verbrugge et al.
CANCER RESEARCH (2012)
A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
Dung T. Le et al.
CLINICAL CANCER RESEARCH (2012)
The Pancreas Cancer Microenvironment
Christine Feig et al.
CLINICAL CANCER RESEARCH (2012)
Cancer stem cells
Zuoren Yu et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
Ghassan K. Abou-Alfa et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation
Eric Lutz et al.
ANNALS OF SURGERY (2011)
Transition of tumor-associated macrophages from MHC class IIhi to MHC class IIlow mediates tumor progression in mice
Benfan Wang et al.
BMC IMMUNOLOGY (2011)
Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor
Soo-Hyun Kim et al.
JOURNAL OF ENDOCRINOLOGY (2011)
Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
Jayme B. Stokes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Targeting the Tumor Microenvironment in Cancer: why Hyaluronidase Deserves a second Look
Clifford J. Whatcott et al.
CANCER DISCOVERY (2011)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2010)
Immune responses to malignancies
Theresa L. Whiteside
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TAN
Zvi G. Fridlender et al.
CANCER CELL (2009)
Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer
Carolyn E. Clark et al.
CANCER LETTERS (2009)
Regulatory T cells: how do they suppress immune responses?
Shimon Sakaguchi et al.
INTERNATIONAL IMMUNOLOGY (2009)
BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
Cristina R. Ferrone et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation
Dan Laheru et al.
CLINICAL CANCER RESEARCH (2008)
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Carolyn E. Clark et al.
CANCER RESEARCH (2007)
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Daruka Mahadevan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Hyperactive Ras in developmental disorders and cancer
Suzanne Schubbert et al.
NATURE REVIEWS CANCER (2007)
Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients
Tetsuya Ikemoto et al.
PANCREAS (2006)
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions
Nobuyoshi Hiraoka et al.
CLINICAL CANCER RESEARCH (2006)
Metastasis: a question of life or death
P Mehlen et al.
NATURE REVIEWS CANCER (2006)
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
DG Brockstedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Biological significance of focal adhesion kinase in ovarian cancer - Role in migration and invasion
AK Sood et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Issues and progress with protein kinase inhibitors for cancer treatment
J Dancey et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Stromal antigen targeting by a humanised monoclonal antibody:: An early phase II trial of sibrotuzamab in patients with metastatic colorectal cancer
RD Hofheinz et al.
ONKOLOGIE (2003)
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:: Clinical and immunological responses in patients with pancreatic adenocarcinoma
MK Gjertsen et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation
EM Jaffee et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A
E Chuang et al.
IMMUNITY (2000)
分享论文
